Harvard Bioscience (HBIO) Assets Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Assets Average data on file, last reported at $79.0 million in Q1 2026.

• Quarterly Assets Average fell 23.46% year-over-year to $79.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.0 million (down 23.46% YoY) and the FY2025 annual result came in at $103.4 million, down 21.7% from the prior year.
• Assets Average held at $79.0 million in Q1 2026 per HBIO's latest filing, from $79.0 million in the prior quarter.
• Across five years, Assets Average topped out at $160.2 million in Q1 2022 and bottomed at $79.0 million in Q1 2026.
• The 5-year median for Assets Average is $135.3 million (2024), against an average of $125.3 million.
• The widest annual swing landed in 2022, when Assets Average climbed 4.19%; it then tumbled 39.23% in 2025.
• Tracing HBIO's Assets Average over 5 years: stood at $146.2 million in 2022, then retreated by 5.22% to $138.6 million in 2023, then dropped by 6.94% to $128.9 million in 2024, then sank by 38.71% to $79.0 million in 2025, then slipped by 0.03% to $79.0 million in 2026.
• Per Business Quant, the three latest HBIO Assets Average figures stand at $79.0 million (Q1 2026), $79.0 million (Q4 2025), and $79.0 million (Q3 2025).

Peer Comparison